(secondQuint)An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis.

 A decision was made to switch all patients on fingolimod 1.

25 mg/day to fingolimod 0.

5 mg/day in an amendment to the study protocol.

 The study became open-label with all patients receiving fingolimod 0.

5 mg/day on 22 Feb 2010.

 The efficacy data for Months 0-6 in this study report is from the core study NCT00537082.

.

 An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis@highlight

This study was an extension study of NCT00537082.

 This study was designed to evaluate the efficacy and safety of long-term administration of 0.

5 mg or 1.

25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.

